Appendageal malignancies

Cancer Treatment and Research

Volumn 146, Issue , 2009, Pages 353-374

  Harwood, Catherine A ^a,b   Proby, Charlotte M ^c   Cerio, Rino ^a  

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^b BARTS HEALTH NHS TRUST   (United Kingdom)

^c UNIVERSITY OF DUNDEE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CYCLOSPORIN; IMMUNOSUPPRESSIVE AGENT; RAPAMYCIN;

ADENOCARCINOMA; ANTINEOPLASTIC ACTIVITY; APPENDAGEAL TUMOR; CANCER CLASSIFICATION; CANCER INCIDENCE; CANCER RISK; CANCER SUSCEPTIBILITY; CLINICAL FEATURE; DRUG METABOLISM; GENETIC PREDISPOSITION; GRAFT RECIPIENT; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; MICROCYSTIC ADNEXAL CARCINOMA; NONHUMAN; ORGAN TRANSPLANTATION; OUTCOME ASSESSMENT; POROCARCINOMA; PRIORITY JOURNAL; REVIEW; SEBACEOUS CARCINOMA; SEBACEOUS GLAND TUMOR; SKIN APPENDAGE DISEASE; SKIN CANCER; SWEAT GLAND CARCINOMA; SWEAT GLAND TUMOR; SYRINGOCYSTADENOMA PAPILIIFERUM; TUBEROUS SCLEROSIS; ULTRAVIOLET RADIATION; WART VIRUS; BIOLOGICAL MODEL; CARCINOMA, SKIN APPENDAGE; CELL DIFFERENTIATION; FEMALE; IMMUNE SYSTEM; MALE; MIDDLE AGED; PATHOLOGY; PROGNOSIS; SKIN NEOPLASMS; TREATMENT OUTCOME;

ADENOCARCINOMA, SEBACEOUS; CARCINOMA, SKIN APPENDAGE; CELL DIFFERENTIATION; FEMALE; HUMANS; IMMUNE SYSTEM; IMMUNOSUPPRESSIVE AGENTS; MALE; MIDDLE AGED; MODELS, BIOLOGICAL; ORGAN TRANSPLANTATION; PROGNOSIS; SKIN NEOPLASMS; TREATMENT OUTCOME;

EID: 77953670863     PISSN: 09273042     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-0-387-78574-5_29     Document Type: Review

References (71)

1. LeBoit PE. Appendageal skin tumours: Introduction. In: World Health Organisation Classification of Tumours: Skin Tumours (Edited by LeBoit PE, Burg G, Weedon D, Sarasin A); IARC Press, Lyon, 2006. pp 123-4.
2. Alsaad KO, Obaidat NA, Ghazarian D. Skin adnexal neoplasms-part 1: an approach to tumours of the pilosebaceous unit. J Clin Pathol. 2007; 60:129-44.
3. Levi Z, Hazazi R, Kedar-Barnes I, Hodak E, Gal E, Mor E, Niv Y, Winkler J.. Switching from tacrolimus to sirolimus halts the appearance of new sebaceous neoplasms in Muir-Torre syndrome. Am J Transplant. 2007; 7(2):476-9.
4. Kazakov DV, Calonje E, Zelger B, Luzar B, Belousova IE, Mukensnabl P, Michal M. Sebaceous carcinoma arising in nevus sebaceus of Jadassohn: a clinicopathological study of five cases. Am J Dermatopathol. 2007; 29(3):242-8.
5. Liegl B, Leibl S, Okcu M, Beham-Schmid C, Regauer S. Malignant transformation within benign adnexal skin tumours. Histopathology. 2004; 45(2):162-70.
6. Kose R, Coban YK, Ciralik H. Eccrine porocarcinoma arising from preexisting eccrine poroma of the scalp after radiotherapy for cervical cancer. Dermatol Online J. 2006; 12(6):18.
7. Obaidat NA, Alsaad KO, Ghazarian D. Skin adnexal neoplasms-part 2: an approach to tumours of cutaneous sweat glands. J Clin Pathol. 2007; 60:145-59.
8. Stone MS, Duncan WC, McGavran MH. Torre's syndrome: exacerbation of cutaneous manifestations with immunosuppression. J Am Acad Dermatol. 1986; 15:1101-3.
9. Warschaw KE, Eble JN, Hood AF, Wolverton SE, Halling KC. The Muir-Torre syndrome in a black patient with AIDS: histopathology and molecular genetic studies. J Cutan Pathol. 1997:24;511-518.
10. Dover JS, Ashur ML, Kwan TH. Sebaceous adenoma in a patient with acquired immunodeficiency syndrome. Arch Dermatol. 1988; 124:489-90.
11. Paraf F, Sasseville D, Watters AK, Naod S, Ginsburg O, Shibata H, Jothy S. Clinicopathological relevance of the association between gastrointestinal and sebaceous neoplasms: the Muir-Torre syndrome. Hum Pathol. 1995; 26:422-7.
12. Stockl FA, Dolmetsch AM, Codére F, Burnier MN. Sebaceous carcinoma of the eyelid in an immunocompromised patient with Muir-Torre syndrome. Can J Opthalmol. 1995; 30:324-6.
13. Yen MT, Tse DT. Sebaceous cell carcinoma of the eyelid and the human immunodeficiency virus. Opthal Plast Reconstr Surg. 2000; 16:206-10.
14. Kuwahara RT, Rudolph TM, Skinner RB, Rasberry RD. A large ulcerated tumour on the back. Arch Dermatol. 2001; 137:1367-72.
15. Mahlberg MJ, McGinnis KS, Draft KS, Fakharzadeh SS. Multiple eccrine poromas in the setting of total body irradiation and immunosuppression. J AmAcad Dermatol. 2006 Aug;55(2 Suppl):S46-9.
16. Blohme I, Larko O. Premalignant and malignant skin lesions in renal transplant patients. Transplantation. 1984; 37:165-167.
17. Oh JE, Ahn C, Yang JS, Min KW, Song KY, Kim SJ, Han JS, Kim S, Lee JS. Malignant proliferating trichilemmal tumour in renal transplantation. Nephrol Dial Transplant. 1997; 12(12):2768-71.
18. Happenreijs VPT, Reuser TTQ, Maay CM, De Keizer RJW, Maurits MP. Syringomatous carcinoma of the eyelid and orbit: a clinical and histopathological challenge. Br J Ophthamol. 1997; 81:668-72.
19. Chastain MA,Millikan LE. Pilomatrix dysplasia in an immunosuppressed patient. J Am Acad Dermatol. 2000; 43:118-22.
20. Ramsay HM, Fryer AA, Reece S, Smith AG, Harden PN. Clinical risk factors associated with nonmelanoma skin cancer in renal transplant recipients. Am J Kidney Dis. 2000; 36(1):167-76.
21. Euvrard S, Kanitakis J, Cochat P, Cambazard F, Claudy A. Skin diseases in children with organ transplants. J Am Acad Dermatol. 2001; 44(6):932-9.
22. Snow S, Madjar DD, Hardy S, Bentz M, Lucarelli MJ, Bechard R, Aughenbaugh W, McFadden T, Sharata H, Dudley C, Landeck A. Microcystic adnexal carcinoma: report of 13 cases and review of the literature. Dermatol Surg. 2001; 27(4):401-8.
23. Plunkett TA, Hanby AM,Miles DW, Rubens RD.Metastatic eccrine porocarcinoma: Response to docetaxel (Taxotere). Ann Oncol. 2001; 12:411-414.
24. Garrett AB, Scott KA. Trichilemmal carcinoma: a case report of a rare skin cancer occurring in a renal transplant patient. Transplantation. 2003; 76(7):1131.
25. Bordea C, Wojnarowska F, Millard PR, Doll H, Welsh K, Morris PJ. Skin cancers in renaltransplant recipients occur more frequently than previously recognized in a temperate climate. Transplantation. 2004; 77(4):574-9. Review.
26. Mudhar HS, Parsons MA, Farr R, Ford A, Gudgeon P, Collins C, Chang BY. Steatosebocystadenoma: a novel cystic sebaceous neoplasm in an immunosuppressed individual. Histopathology. 2005; 47(4):429-3.
27. Harwood CA, McGregor JM, Swale VJ, Proby CM, Leigh IM, Newton R, Khorshid SM, Cerio R. High frequency and diversity of cutaneous appendageal tumors in organ transplant recipients. J Am Acad Dermatol. 2003; 48(3):401-8.
28. Heaphy MR, Shamma HN, Hickmann M, White MJ. Cyclosporine-induced folliculodystrophy. J Am Acad Dermatol. 2004; 50:318-22.
29. Harwood CA, Swale VJ, Bataille VA, Quinn AG, Ghali L, Patel SV et al. An association between sebaceous carcinoma and microsatellite instability in immunosuppressed organ transplant recipients. J Invest Dermatol; 2001; 116:246-53.
30. O'Donovan P, Perrett CM, Zhang X, Montaner B, Xu YZ, Harwood CA, McGregor JM, Walker SL, Hanaoka F, Karran P. Azathioprine and UVA light generate mutagenic oxidative DNA damage. Science. 2005; 309(5742):1871-4.
31. Brash DE, Rudolph JA, Simon JA, Lin A, McKenna GJ, Baden HP, Halperin AJ, Ponten J. A role for sunlight in skin cancer: UV induced p53 mutations in squamous-cell carcinoma. Proc Natl Acad Sci USA.1991;88:10124-8.
32. De Gruijl FR. Skin cancer and solar UV radiation. Eur J Cancer. 1999; 35:2003-9.
33. Boukamp P. Non-melanoma skin cancer: what drives tumor development and progression? Carcinogenesis. 2005; 26:1657-87.
34. Ullrich SE. Mechanisms underlying UV-induced immune suppression. Mutation Res. 2005; 571:185-205.
35. Kruse R, Rutten A, Lamberti C, Hosseiny-Malayeri HR, Wang Y, Ruelfs C, Jungck M, Mathiak M, Ruzicka T, Hartschuh W, Bisceglia M, FriedlW, Propping P.Muir-Torre phenotype has a frequency of DNA mismatch-repair-gene mutations similar to that in hereditary nonpolyposis colorectal cancer families defined by the Amsterdam criteria. Am J Hum Genet. 1998; 63:63-70.
36. Bignell GR, Warren W, Seal S, Takahashi M, Rapley E, Barfoot R, Green H, Brown C, Biggs PJ, Lakhani SR, Jones C, Hansen J, Blair E, Hofmann B, Siebert R, Turner G, Evans DG, Schrander-Stumpel C, Beemer FA, van Den Ouweland A, Halley D, Delpech B, Cleveland MG, Leigh I, Leisti J, Rasmussen S. Identification of the familial cylindromatosis tumoursuppressor gene. Nat Genet. 2000; 25(2):160-5.
37. Leonard N, Chaggar R, Jones C, Takahashi M, Nikitopoulou A, Lakhani SR. Loss of heterozygosity at cylindromatosis gene locus CYLD, in sporadic skin adnexal tumours. J Clin Pathol. 2001; 54:689-92.
38. Harada H, Hashimoto KY, Ko MSH. The gene for multiple trichoepitheliomas maps to chromosome 9p21. J Invest Dermatol. 1996; 107:41-43.
39. Matt D, Xin H, Vortmeyer AO, Zhuang Z, Burg G, Boni R. Sporadic trichoepithelioma demonstrates deletions at 9q22.3. Arch Dermatol. 2000; 136:657-60.
40. Liaw D, Marsh DJ, Li J, Dahia PL, Wang SI, Zheng Z, Bose S, Call KM, Tsou HC, Peacocke M, Eng C, Parsons R. Germline mutations of the PTEN gene in Cowden disease, an inherited breast and thyroid cancer syndrome. Nat Genet. 1997; 16(1):64-7.
41. Sundberg JP, O'Banion MK, Shima A, Knupp C, Reichmann ME. Papillomas and carcinomas associated with a papillomavirus in European Harvest mice (Micromys minutus). Vet Pathol. 1988; 25:356-61.
42. Herber R, Liem A, Pitot H et al. Squamous epithelial hyperplasia and carcinoma in mice transgenic for the human papillomavirus type 16E7 oncogene. J Virol. 1996; 70:1873-81.
43. Hayashi N, Furihata M, Ohtsuki Y, Ueno H. Search for accumulation of p53 protein and detection of human papillomavirus genomes in sebaceous gland carcinoma of the eyelid. Virchows Archiv. 1994; 424:503-9.
44. Rohwedder A, Keminer O, Hendricks C, Scaller J. Detection of HPV DNA in trichilemmomas by polymerase chain reaction. J Med Virol. 1997; 51:119-25.
45. Leonardi CL, Zhu WY, Kinsey WH, Penneys NS. Trichilemmomas are not associated with human papillomavirus DNA. J Cutan Pathol. 1991; 18(3):193-7.
46. Assadoullina A, Bialasiewicz AA, de Villiers EM, Richard G. Detection of HPV-20, HPV-23, and HPV-DL332 in a solitary eyelid syringoma. Am J Ophthalmol. 2000; 129:99-101.
47. Carlson JW, McGennen RC, Gomez R, Longbella C, Carter J, Carson LF. Sebaceous carcinoma of the vulva: a report and review of the literature. Gynecol Oncol. 1996; 60: 489-91.
48. Escalonilla P, Grilli R, Canamero M, Soriano ML, Frina MC, Manzarbeitia F, Sainz R, Matsukura T, Requena L. Sebaceous carcinoma of the vulva. Am J Dermatopathol. 1999; 21:468-72.
49. Egawa K. Eccrine-centred distribution of human papillomavirus 63 infection in the epidermis of the plantar skin. Br J Dermatol. 2005; 152(5):993-6.
50. Hsu PJ, Liu CH, Huang CJ. Mixed tubulopapillary hidradenoma and syringocystadenoma papilliferum occurring as a verrucous tumor. J Cutan Pathol. 2003; 30(3):206-10.
51. Requena L, Kutzner H, Hurt MA, Danta Cruz DJ, Mehregan DA, Mehregan DR, Mengesha YM, Kohler S, Argenyi ZB, McNiff J, Rudolph P, Sangueza OP. Malignant tumours with apocrine and eccrine differentiation. In:World Health Organisation Classification of Tumours: Skin Tumours (Edited by LeBoit PE, Burg G, Weedon D, Sarasin Al); IARC Press, Lyon, 2006. pp. 125-151.
52. Huet P, Dandurand M, Pignodel C, Guillot B. Metastasizing eccrine porocarcinoma: report of a case and review of the literature. J Am Acad Dermatol. 1996; 35(5 Pt 2):860-4.
53. McNiff J, McCalmont TH, Requena L, Sangueza OP, Vassalo C, Rosso R, Borroni G, Glusac EJ, Pichardo RO. Benign tumours with apocrine and eccrine differentiation. pp 139-148. In: World Health Organisation Classification of Tumours: Skin Tumours (Edited by LeBoit PE, Burg G, Weedon D, Sarasin A; IARC Press, Lyon, 2006).
54. de Berker DA, Taylor AE, Quinn AG, Simpson NB. Sebaceous hyperplasia in organ transplant recipients: shared aspects of hyperplastic and dysplastic processes? J Am Acad Dermatol. 1996; 35(5 Pt 1):696-9.
55. Mak R, Perrett C, Proby CM, Harwood CA. Sebaceous gland hyperplasia is common and therapeutically challenging in organ transplant recipients. Br J Dermatol. 2006; 155 (Suppl 1):36.
56. Moloney FJ, Keane S, O'Kelly P, Conlon PJ, Murphy GM. The impact of skin disease following renal transplantation on quality of life. Br J Dermatol. 2005 Sep;153(3):574-8.
57. Salard D, Parriaux N, Derancourt C, Aubin F, Bresson-Hadni S, Miguet JP, Laurent R. Cutaneous complications following liver transplantation: epidemiologic and clinical study in 86 patients. Ann Dermatol Venereol. 2002; 129(10 Pt 1):1134-8.
58. Salim A, Reece SM, Smith AG, Harrison D, Ramsay HM, Harden PN, Fryer AA. Sebaceous hyperplasia and skin cancer in patients undergoing renal transplant. Am Acad Dermatol. 2006; 55(5):878-81.
59. Perrett CM, McGregor J, Barlow RJ, Karran P, Proby C, Harwood CA. Topical photodynamic therapy with methyl aminolevulinate to treat sebaceous hyperplasia in an organ transplant recipient. Arch Dermatol. 2006; 142(6):781-2.
60. Walther T, Hohenleutner U, Landthaler M. Sebaceous gland hyperplasia as a side effect of cyclosporin A. Treatment with the CO2 laser. Dtsch Med Wochenschr. 1998; 123(25- 26):798-800.
61. Pang SM, Chau YP. Cyclosporin-induced sebaceous hyperplasia in renal transplant patients. Ann Acad Med Singapore. 2005; 34(5):391-3.
62. Harwood CA, Proby CM, McGregor JM, Sheaff MT, Leigh IM, Cerio R. Clinicopathologic features of skin cancer in organ transplant recipients: a retrospective case-control series. J Am Acad Dermatol. 2006; 54(2):290-300.
63. Torre D. Multiple sebaceous tumours. Arch Dermatol. 1968; 98:549-51.
64. Jiricny J. Replication errors: cha(lle)nging the genome. EMBO J. 1998; 22:6427-36.
65. Boland CR, Thibodeau SN, Hamilton SR, Sidransky D, Eshleman JR, Burt RW, Meltzer SJ, Rodriguez-Bigas MA, Fodde R, Ranzani GN, Srivastava S. A National Cancer Institute workshop on microsatellite instability for cancer detection and familial predisposition: development of international criteria for the determination of microsatellite instability in colorectal cancer. Cancer Res. 1998; 58:5248-5257.
66. Swann PF, Waters TR, Moulton DC, Xu Y-Z, Zheng Q, Edwards M, Mace R. Role of postreplicative DNA mismatch repair in the cytotoxic action of thioguanine. Science. 1996; 273:1109-11.
67. Karran P, Bignami M. DNA damage tolerance, mismatch repair and genome instability. BioEssays. 1994; 16:833-9.
68. Glaab WE, Risinger JI, Umar A, Barrett JC, Kunkel TA, Tindall KR. Resistance to 6- thioguanine in mismatch repair-deficient human cancer cell lines correlates with an increase in induced mutations at the HPRT locus. Carcinogenesis. 1998; 19(11):1931-7.
69. Zouboulis CC, Boschnaknow A. Chronological ageing and photoageing in the human sebaceous gland. Clin Exp Dermatol. 2001; 26:600-7.
70. Perrett CM, Walker SL, O'Donovan P, Warwick J, Harwood CA, Karran P, McGregor JM Azathioprine treatment photosensitizes human skin to ultraviolet A radiation. Br J Dermatol. 2008; 159(1):198-204.
71. Lindelof B, Sigurgeirsson B, Gabel H, Stern RS. Incidence of skin cancer in 5356 patients following organ transplantation. Br J Dermatol. 2000; 143:614-18.